[New therapeutic strategies in chronic hepatitis C].
Pawlotsky
Jean-Michel
JM
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use; D016174:Hepacivirus / Q000187:drug effects / Q000201:enzymology; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000031:analogs & derivatives / Q000627:therapeutic use; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use; D012709:Serum Albumin / Q000627:therapeutic use; D000075462:Serum Albumin, Human; D014764:Viral Proteins / Q000037:antagonists & inhibitors; D014765:Viral Vaccines
D000998:Antiviral Agents; D016756:Immunoglobulins, Intravenous; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D015842:Serine Proteinase Inhibitors; D012709:Serum Albumin; D014764:Viral Proteins; D014765:Viral Vaccines; C473631:albuferon; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a; C026956:taribavirin; D000075462:Serum Albumin, Human